Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone Cancer

Descrizione del progetto

Un migliore monitoraggio del trattamento del tumore osseo metastatico

Il tumore osseo metastatico è incurabile e difficile da trattare, cosa ulteriormente complicata dall’impossibilità di monitorare i tumori durante la radioterapia con particelle standard (PRT). La diagnostica per immagini del tumore viene attualmente eseguita solo all’inizio e alla fine della PRT a causa dell’elevata dose di radiazioni richiesta. Il progetto BoneOscopy, finanziato dal Consiglio europeo per l’innovazione, mira a consentire il monitoraggio quotidiano con un’analisi spettroscopica accurata di volumi tumorali molto piccoli, rilevando i segnali emessi dalle cellule cancerose durante la PRT senza radiazioni aggiuntive. Sfruttando innovazioni matematiche e software all’avanguardia, BoneOscopy consentirà un’analisi quantitativa sicura e personalizzata dell’efficacia del trattamento con il potenziale di migliorare gli esiti dei pazienti, ridurre i costi sanitari e rendere l’assistenza sanitaria più sostenibile.

Obiettivo

Metastatic bone cancer is an incurable disease and one of the most complex cancers to treat. Due to the high dose, tumour imaging is currently performed at the beginning and end of standard particle radio-therapy (PRT), making personalised treatment difficult. The main goal of BoneOscopy is to develop a radically new technology to enable informed medical decisions by monitoring bone cancer on a daily basis during PRT. At the heart of BoneOscopy is the ability to detect prompt gamma (PGs) emitted by cancer during PRT and separate them from healthy tissue, unlocking the full potential of spectroscopic analysis without the need for additional dose. The development of a highly specialised detection and collimation system will enable accurate spectroscopic analysis of a very small volume or region within the cancer. As the number of PRT centres grows, we anticipate that within 10 years BoneOscopy will benefit all patients treated with proton and carbon ions. The objectives of BoneOscopy will be achieved by its interdisciplinary consortium, which brings together six partners from five European countries with key expertise in bioengineering and PRT (DKFZ), medical physics and engineering (CSIC), fast electronics for PRT (LIP), Monte Carlo simulations and clinical PRT experience (THM), turnkey software for high performance medical devices (Cosylab) and EU project management, communication and dissemination (accelCH). If achieved, the proposed science-to-technology breakthrough will have a transformative impact on current cancer treatment by providing a safe, personalised and quantitative measure of daily treatment efficacy, thereby contributing to the global fight against cancer. In summary, BoneOscopy will lead to a significant reduction in the health burden in Europe and worldwide, improved quality of life for patients, reduced costs for healthcare systems and improved sustainability of healthcare.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC - HORIZON EIC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2024-PATHFINDEROPEN-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Contributo netto dell'UE
€ 815 875,00
Indirizzo
IM NEUENHEIMER FELD 280
69120 Heidelberg
Germania
Regione
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 815 875,00

Partecipanti (4)

Partner (1)